Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in India

Novo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patient access. These new prices, effective April 1, aim to make the GLP-1 therapies more affordable for individuals managing diabetes and obesity. This move comes as Indian companies launch generic semaglutide following patent expiry, intensifying market competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6dhBEot
via IFTTT